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Abstract Morphine is considered the “gold standard” for
relieving pain and is currently one of the most effective drugs
available clinically for the management of severe pain
associated with cancer. In addition to its use in the treatment
of pain, morphine appears to be important in the regulation of
neoplastic tissue. Although morphine acts directly on the
central nervous system to relieve pain, its activities on
peripheral tissues are responsible for many of the secondary
complications. Therefore, understanding the impact, other
than pain control, of morphine on cancer treatment is
extremely important. The effect of morphine on tumorgrowth
is still contradictory, as both growth-promoting and growth-
inhibitingeffects havebeenobserved.Accumulatingevidence
suggests that morphine can affect proliferation and migration
of tumor cells as well as angiogenesis. V arious signaling
pathways have been suggested to be involved in these extra-
analgesic effects of morphine. Suppression of immune system
by morphine is an additional complication. This review
provides an update on the influence of morphine on the
growth and migration potential of tumor cells.
Keywords Apoptosis.Proliferation.Angiogenesis.
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Abbreviations
BAD Bcl-xL/Bcl-2-associated death promoter protein
CNS Central nervous system
COX-2 Cyclooxygenase-2
ECM Extracellular matrix
EGF Epidermal growth factor
Erk Extracellular-regulated kinase
IL Interleukin
JNK c-Jun N-terminal kinase
MAPK Mitogen-activated protein kinase
MMPs Matrix metalloproteinases
MNTX Methylnaltrexone
NF-κB Nuclear factor κB
NO Nitric oxide
NOS Nitric oxide synthase
PAI-1 Plasminogen activator inhibitor-1
PAI-2 Plasminogen activator inhibitor-2
PGE2 Prostaglandin E2
PI3K Phosphatidylinositol 3-kinase
RhoA Ras homolog gene family, member A
ROS Reactive oxygen species
Src Non-receptor tyrosine kinase
TIMPs Tissue inhibitors of metalloproteinases
TNF Tumor necrosis factor
uPA Urokinase plasminogen activator
uPAR Urokinase plasminogen activator membrane-
linked receptor
VEGF V ascular endothelial growth factor
Introduction
Morphine, the main component of opium, is perhaps the
oldest drug known to man. Pure morphine was isolated in
1803 by Sertürner (Schmitz 1985), and its structure was
elucidated 120 years later. Full systemic name of morphine
is 7,8-didehydro-4,5-epoxy-17-methyl-(5α,6 α)-mor-
phinan-3,6-diol. Morphine was found to be a particularly
good analgesic and sedative, far more effective than crude
K. Gach:A. Wyrębska: J. Fichna: A. Janecka (*)
Department of Biomolecular Chemistry,
Medical University of Lodz,
Mazowiecka 6/8,
92-215 Lodz, Poland
e-mail: anna.janecka@umed.lodz.pl
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230
DOI 10.1007/s00210-011-0672-4opium. Morphine was shown to exert its action through
opioid receptors (μ, δ,a n dκ) localized in the brain
(Pasternak 1993; Reisine and Bell 1993; Harrison et al.
1998; Kieffer 1999; Kieffer and Gaveriaux-Ruff 2002).
However, morphine binds to the μ-opioid receptor with
nearly two orders of magnitude greater affinity compared
with the other two opioid receptors (Zadina et al. 1994).
Although morphine acts directly on the central nervous
system (CNS) to relieve pain, its activity on peripheral
tissues is responsible for many of the secondary complica-
tions. Besides its strong analgesic effect, morphine exerts a
number of adverse side-effects, including addiction, toler-
ance, respiratory depression, immunosuppression, and
constipation. The lack of equally strong painkillers is the
reason that despite the drawbacks mentioned above,
morphine is still the most commonly used analgesic for
management of severe pain, including cancer pain (Mantyh
2006). Administration of morphine to cancer patients gave
evidence that apart from its analgesic action, morphine can
significantly alter tumor growth. In the last decade,
numerous studies employing cancer cell lines and experi-
mental animals have been performed to reveal complex
mechanisms by which morphine affects tumor cells.
Whereas the pharmacology and function of opioids in the
CNS have been extensively characterized, still little is
known about their effect on cancer cells. The results
obtained so far are conflicting. In the past, morphine was
reported to increase the proliferation of endothelial and
tumor cells (Simon and Arbo 1986; Moon 1988; Ishikawa
et al. 1993; Gupta et al. 2002). On the other hand, morphine
and other opioids were also found to promote tumor cell
death (Maneckjee et al. 1990; Yeager and Colacchio 1991;
Page et al. 1993; Hatzoglou et al. 1996; Sueoka et al. 1996,
1998). Several reviews have covered this important
research area from different perspectives (Rasmussen et al.
2002; Fichna and Janecka 2004; Tegeder and Geisslinger
2004; Chen et al. 2008). This review will focus on the latest
findings on the influence of morphine on tumor cell
proliferation, apoptosis, angiogenesis, and migration.
Effect of morphine on tumor growth
Despite extensive research, it is still not well understood
whether morphine itself directly modifies the growth of
tumor cells. Some authors postulate that morphine can
promote tumor growth and reduce the survival rate of
tumor-bearing animals due to immunosuppression, since
the negative effects of morphine and other opioids on the
immune system are well established (Odunayo et al. 2010).
On the other hand, multiple research data indicate that
morphine can accelerate or inhibit cancer cell growth in
vitro and in vivo by different mechanisms.
High concentrations of morphine were shown to reduce the
growth of tumors. Tegeder et al. (2003) reported that morphine
inhibited tumor cell proliferation at concentrations of >10 μM.
In nude mice, morphine significantly reduced the growth of
MCF-7 and MDA-MB-231 tumors. Intermittent injections of
morphine decreased the growth of tumors in a rat model of
metastasizing colon cancer (Yeager and Colacchio 1991).
On the other hand, morphine was shown to trigger
stimulation of human glioblastoma T98G cell proliferation
(Lazarczyk et al. 2010). Gupta et al. (2002) demonstrated
that morphine, in clinically relevant doses, promoted tumor
neovascularization in a human breast tumor xenograft
model in mice, leading to increased tumor progression.
The discrepancies in results may be due to the differ-
ences in administered doses or/and the mode of adminis-
tration (systemic versus localized). These examples, as well
as some other reports (Maneckjee et al. 1990; Harimaya et
al. 2002;S a s a m u r ae ta l .2002), showed that tumor
suppression occurs after chronic high doses of morphine,
while tumor-enhancing effects with morphine occur after a
single dose or low daily doses (Zong and Pollack 2000).
This dual concentration-dependent effect, i.e., mitogenesis
at low and growth inhibition at higher concentrations was
observed both in vitro and in vivo.
The lack of effects of morphine on the proliferation of
colon cancer HT-29 cells (Zagon et al. 1996; Nylund et al.
2008) and on breast cancer MCF-7 cells was also reported
(Janecka et al. 2004).
Recently, it was demonstrated that the μ-opioid receptor
regulates cancer progression in animal models (Moss and
Rosow 2008; Wang et al. 2009; Singleton and Moss 2010).
The μ-opioid receptor-knockout mice were shown not to
develop significant tumors when injected with Lewis lung
cancer cells as did the wild-type controls (Mathew et al.
2009). Silencing the expression of the μ-opioid receptor in
Lewis lung cancer cells inhibited lung metastasis in wild-
type mice by about 75%. Finally, infusion of the μ-opioid
receptor antagonist, methylnaltrexone, markedly attenuated
tumor growth in wild-type mice treated with Lewis lung
cancer cells by up to 90% (Mathew et al. 2009). These
experimental data strongly support the hypothesis that the
μ-opioid receptor promotes tumor growth and metastasis.
Possible mechanisms of morphine action mediated
through the opioid receptors are demonstrated in Fig. 1
and through the non-opioid pathways in Fig. 2.T h e
summary of in vivo growth-promoting and growth-
inhibiting effects of morphine is presented in Table 1.
Effect of morphine on tumor apoptosis
Apoptosis is an active process of controlled cell death in the
development and maintenance of tissue homeostasis.
222 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230Apoptosis is controlled by two main pathways, the intrinsic
or the mitochondrial-mediated pathway (Green and Reed
1998) and the extrinsic or death receptor-mediated pathway
(Ashkenazi and Dixit 1999). Mitochondrial-mediated apo-
ptosis is controlled by Bcl-2 family of proteins (Cory and
Adams 2002;C o r ye ta l .2003). The death receptor-
mediated pathway is initiated by the ligation of cell death
ligands with their death receptors (Sartorius et al. 2001).
Caspase-3 is activated in both apoptotic pathways and plays
central role in the execution phase of cell apoptosis
(Ashkenazi and Dixit 1999; Hengartner 2000; Fulda and
Debatin 2006).
Apoptosis is usually deregulated in cancer cells, and this
deregulation can contribute to uncontrollable proliferation
and tumor growth (Hanahan and Weinberg 2000; Hengartner
2000; Kaufmann and Hengartner 2001). Morphine was
shown to induce the apoptosis of human endothelial cells
(Hsiao et al. 2009) and of T lymphocytes and macrophages
(Kapasi et al. 2004). Morphine in high concentrations (10
−3–
10
−6 M) was demonstrated to induce apoptotic cell death in
human tumor cell lines (Kawase et al. 2002; Hatsukari et al.
2003). In other studies, the pro-apoptotic effect of morphine
in human tumor cell lines was observed at clinical
concentration (10
−8 M) (Smith et al. 1999; Hatsukari et al.
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Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230 223Table 1 Summary of in vivo growth-promoting and growth-inhibiting effects of morphine
Cell line/tumor
type
In vivo effects In vivo dose/time Suggested mechanism Antagonist/inhibition Ref.
Ehrlich
carcinoma
injected s.c. in
the left thigh of
BALB/c mice
Stimulation of
angiogenesis
0.714 mg/kg/day for
7 days (equivalent to
50 mg per day for a
70 kg human)
Ustun et al.
2010
Colon cancer
cells injected i.
p. in Fisher 344
rats
Inhibition of tumor
growth and metastasis
(significant decrease
in the hepatic tumor
burden)
20 mg/kg/day s.c., the
day before and for
2 days after colon
cancer cell inoculation
Enhancement of NK cell
activity at the time of
tumor cell injection
Yeager and
Colacchio
1991
MCF-7, MDA-
MB231 breast
cancer or HT-
29 colon cancer
cells injected s.
c. in NMRI-nu/
nu mice
Inhibition of tumor
growth (MCF-7 and
MDA-MB231) no ef-
fect on HT-29 tumors
10–30 mg/kg/day i.p. for
3 weeks (stepwise 10,
20, and 30 mg/kg/
day i.p. for the first,
second, and third week)
Inhibition of tumor
growth through a p53
dependent mechanism
(up-regulation of p53-
dependent p21, Bax,
Fas)
Naloxone increased the
growth-inhibitory
effects of morphine
Tegeder et
al. 2003
EL-4 leukemia in
C57Bl6 mice,
sarcoma 180 in
ddY mice
Increase of tumor
growth
10 mg/kg/day s.c. for
10 days
General
immunosuppressive
effect
Naloxone itself had no
significant effect. The
effect was inhibited
by preadministration
of naloxone
Ishikawa et
al. 1993
Walker 256
carcinosarcoma
cells injected i.
v. in Sprague–
Dawley rat
Increase of the number
metastases
5 mg/kg single dose Suppresion of NK cells Naloxone itself had no
significant influence
on the number of
metastases. The effect
was inhibited by
preadministration of
naloxone
Simon and
Arbo
1986
B16-BL6
melanoma cells
injected into
hindpaw in
C57Bl mice
Inhibition of tumor
growth and metastasis
(decreased number of
tumor nodules in the
lung)
5 and 10 mg/kg/day s.c.
for 6 days, starting
16 days after cancer
cells injection
Pain reduction and
blockade of pain
signals
Sasamura
et al.
2002
Colon 26-L5 car-
cinoma cells
injected i.v. in
BALB/c mice
Inhibition of tumor
metastasis (reduction of
the number of tumor
colonies in the lung)
10 mg/kg/day i.p. for
6 days, starting on day
2 after i.v. inoculation
of tumor cells
Inhibition of adhesion and
invasion of cancer cells
(inhibition of MMP-2
and 9 production)
Harimaya
et al.
2002
MCF-7 cells
injected into
the mammary
fat pad of nude
mice
Increase of tumor
growth associated
with increased
angiogenesis
(neovascularization,
increased microvessel
density, higher vessel
number, increased
total length, and more
vessel branching)
0.714 mg/kg mouse/day
for first 15 days and
then 1.43 mg/kg
mouse/day (equivalent
to 50 mg and 100 mg
morphine per day,
respectively, for a
70 kg human)
Activation of PI3K/Akt
and Erk pathways,
resulting in inhibition
of apoptosis and
promotion of cell cycle
progression
Naloxone itself had no
significant effect on
angiogenesis. The
anti-angiogenic effect
of morphine was not
inhibited by naloxone
Gupta et al.
2002
MADB-100
mammary
adenocarcinoma
cells injected i.v.
in Fisher 344
rats, 5 h after
surgery
Inhibition of surgery-
induced increase in
metastasis
5 mg/kg 3 doses (pre,
post and 5 h post
surgery)
Inhibition of
postoperative pain
and stress-induced
immunosuppression
Page et al.
1993
Murine CCL-11
sarcoma cells
injected into
f e m u ro ft h e
right leg in C3H/
HeJ mice
Morphine did not
alter tumor burden
50, 25, 7.5, 2.5 mg/ml
implanted (s.c.) for
7 days following
injection of CCL-11
cells into the femur
King et al.
2007
224 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–2302007). However, significant differences between cell lines
were found. For example, morphine produced a higher
number of necrotic cells in the MCF-7 breast cancer cell line
than in the A549 lung cancer cell line (Hatsukari et al. 2007).
Consistent with some previous studies (Tegeder et al.
2003), it was recently demonstrated that chronic high-dose
morphine treatment was able to cause apoptotic cell death
of SH-SY5Y cells in an opioid receptor-independent
manner (Lin et al. 2009). A pivotal role in this process
was played by c-Jun N-terminal kinase (JNK). Activation
of JNK by morphine led to reactive oxygen species (ROS)
generation and induced cytochrome c release and caspase-
9/3 activation through enhancement of expression of the
pro-apoptotic protein Bim and reduction of expression of
the anti-apoptotic protein Bcl-2. All of these effects of
morphine could be suppressed by the JNK inhibitor. The
key role of the JNK pathway in morphine-induced
mitochondria-dependent apoptosis was further confirmed
by the observation that decreased levels of JNK in cells
transfected with specific small interfering RNA resulted in
resistance to the pro-apoptotic effect of morphine.
It can be concluded that morphine can induce apoptosis
and inhibit the growth of cancer cells by activating different
signal pathways. Apart from the mitochondrial pathway
mentioned above, apoptosis of MCF-7 cells was shown
to be mediated by a novel sigma-2 receptor and p53
and caspase-independent pathway (Crawford et al. 2002;
Crawford and Bowen 2002). CNE2 human epithelial
tumor cell line was reported to undergo apoptosis by the
activation of the κ-opioid receptor via the phospholipase
pathway (Diao et al. 2000).
The growth-inhibitory or apoptosis-inducing effects of
morphine might be directly associated with morphine
tolerance (Wu et al. 1999; Mao et al. 2002) or receptor
desensitization, as assessed by a lack of morphine-
stimulated GTP-ase activity at concentrations that inhibit
tumor growth (Tegeder et al. 2003). Drugs that prevented
the development of morphine tolerance in rats also
prevented cell death (Mao et al. 2002). This close
association between apoptosis and receptor desensitization
suggests that receptor internalization may be the key event
in initiating opioid-evoked cell death.
On the other hand, evidence of the anti-apoptotic activity
of morphine is also accumulating (Suzuki et al. 2003). It
was shown that morphine can antagonize the pro-apoptotic
activity of a well-known anti-tumor drug, doxorubicin, in
neuroblastoma SH-SY5Y cells (Lin et al. 2007). The effect
could not be reversed by naloxone, indicating a non-opioid
receptor-mediated signaling pathway. Further studies
showed that morphine attenuated doxorubicin-induced
apoptosis by the inhibition of ROS generation and
mitochondrial cytochrom c release, as well as by blockade
of nuclear factor κB (NF-κB) transcriptional activation.
NF-κB is a ubiquitous nuclear transcription factor that
plays a major regulatory role in apoptosis and inflamma-
tion. Iglesias et al. (2003) demonstrated that in SH-SY5Y
neuroblastoma cells, morphine (10
−7–10
−5 M) promoted
cell survival after serum deprivation without inducing cell
proliferation, and this effect was fully reversed by nalox-
one. It was shown that in neuronal cells, μ-opioid agonists
do not directly induce apoptosis, but are able to activate the
phosphatidylinositol 3-kinase/Akt (PI3K/Akt) signal trans-
duction pathway, thus leading to cell survival.
Effect of morphine on angiogenesis
Successful tumor growth depends on many aspects, of
which the most important are proliferation of tumor cells
and angiogenesis or the formation of new blood vessels which
Table 1 (continued)
Cell line/tumor
type
In vivo effects In vivo dose/time Suggested mechanism Antagonist/inhibition Ref.
Lewis lung
carcinoma cells
injected s.c. in
nude mice
Reduction of tumor cell-
induced angiogenesis
and tumor growth
A continuous slow-
release morphine pellet
resulting in morphine
plasma levels within
250–400 ng/ml
Suppression of the
hypoxia-induced mito-
chondrial p38
mitogen-activated pro-
tein kinase (MAPK)
pathway
The effect was
abolished with
naltrexone
Koodie et
al. 2010
TC-1 cells
injected s.c.
into the right
leg of C57BL/
6J mice
Dose-dependent
increase of tumor
growth
10 mg/kg i.p., twice
daily from day 10
before tumor injection
Immunosuppression
(μ-opioid receptor
mediated suppression
of T lymphocytes
proliferation,
promotion of apoptosis
of T lymphocytes
through Bcl-2 and Bax
apoptosis-related
molecules)
Cheng et
al. 2006
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230 225are necessary for metastasis (Carmeliet and Jain 2000). To date,
very few studies have investigated the effect of morphine on
tumor cell-induced angiogenesis. Gupta et al. (2002)s h o w e d
that at clinically relevant concentrations, morphine stimulated
human microvascular endothelial cell proliferation and angio-
g e n e s i si nv i t r o ,a n dt h a ti nv i v ot h e s ee f f e c t st r a n s l a t e di n t o
enhanced tumor neovascularization in the MCF-7 breast
cancer model. In addition, this group demonstrated that
morphine promoted activation of vascular endothelial growth
factor (VEGF) receptor and increased metastasis and reduced
survival in animal model of hormone-dependent breast cancer
(Chen et al. 2006;F a r o o q u ie ta l .2007). However, the opioid
receptor antagonist, naloxone, did not inhibit the pro-
angiogenic activity of morphine, indicating that the effect
was not mediated by the typical opioid receptors.
On the other hand, Singleton and Moss (2010) demon-
strated that μ-opioids (morphine) transactivate the VEGF
receptors and promote angiogenesis. The μ-opioid receptor
antagonist methylnaltrexone blocks opioid-induced angio-
genesis in cultured human endothelial cells.
It was postulated that the pro-angiogenic activity of
morphine is connected with the stimulation of mitogen-
activated protein kinase (MAPK) signaling pathway via G
protein-coupled receptors and nitric oxide (NO). Chronic
morphine treatment increased the levels of nitric oxide
synthase (NOS), NO, and cyclooxygenase-2 (COX-2) in
mouse kidney (Stefano et al. 1995; Arerangaiah et al. 2007).
NO stimulated the enzymatic activity of COX-2 (Salvemini
et al. 1993) ,a n da c t i v a t e dC O X - 2i nt u r ni n c r e a s e d
prostaglandin E2 production (Salvemini et al. 1993, 1994;
Nedelec et al. 2001; Birnbaum et al. 2005). Prostaglandin E2
promoted angiogenesis and tumor progression (Griffin et al.
2002; Leahy et al. 2002; Chang et al. 2004). The role of
COX-2 in cancer progression was further studied by
Farooqui et al. (2007). Two weeks of chronic morphine
treatment of experimental mice with highly invasive
SCK breast cancer model stimulated COX-2, prosta-
glandin E2, and angiogenesis, which was accompanied by
increased tumor weight, increased metastasis, and reduced
survival. It was postulated that products of COX-2, such as
prostaglandin E2 produced in tumor cells, act on the tumor
endothelium and promote angiogenesis. Notably, morphine
induced a much stronger expression of COX-2 in tumor cells
than in endothelial cells. Co-administration of COX-2
inhibitor, celecoxib, prevented morphine-induced promotion
of angiogenesis and tumor growth. Therefore, morphine-
induced tumor growth may in part be due to the up-
regulation of COX-2 and prostaglandin E2-mediated stimula-
tion of angiogenesis. It was also shown that morphine did not
have any effect on MCF-7 human breast cancer cell
proliferation in vitro (Farooqui et al. 2006) but stimulated
MCF-7 breast tumor growth by promoting angiogenesis
(Gupta et al. 2002). That means that morphine by itself did
not modulate tumor cell growth in culture, but due to up-
regulation of COX-2 in tumor cells, stimulated angiogenesis in
vivo, resulting in increased tumor growth and metastasis. The
pro-angiogenic activity of morphine was also reported by
Ustun et al. (2010).
Contradictory data on the effect of morphine on
angiogenesis were also published. It is well known that
when the solid tumor grows, new tumor cells are localized
further away from their vascular supply, and low oxygen
tensions or hypoxia stimulate tumor cells to secrete pro-
angiogenic factors (Folkman and D'Amore 1996). A potent
pro-angiogenic factor secreted by hypoxic tumor cells within
developing solid tumor is vascular endothelial growth factor
(VEGF). This factor promotes new blood vessel formation to
sustain tumor growth and initiates endothelial cell prolifer-
ation and migration (Brekken and Thorpe 2001; Ferrara
2004). Balasubramanian et al. (2001)r e p o r t e dt h a tm o r p h i n e
inhibited hypoxia-induced VEGF secretion in rat cardiomyo-
cytes and human umbilical vein endothelial cells and
therefore attenuated the ability of hypoxic tumor cells to
induce angiogenesis. Most recently, the same effect was
observed in a murine Lewis lung carcinoma tumor model
(Koodie et al. 2010). Morphine was administered to mice at
the clinically relevant analgesic doses by implantation of
continuous slow-release pallets. Morphine plasma level
within 250–400 ng/mL was sufficient to significantly reduce
tumor cell-induced angiogenesis and tumor growth. The
effect of morphine was abolished by concomitant adminis-
tration of opioid antagonist, naltrexone, and also in the μ-
opioid receptor knockout mice, supporting the involvement
of classical opioid receptors in the process. The authors also
demonstrated that the inhibitory effect of morphine was
mediated through the suppression of the hypoxia-induced
mitochondrial p38 MAPK pathway.
Much earlier, it was shown that high concentrations of
morphine (10 mg/mL ofplasma) inhibited angiogenesisin the
chick chorioallantoic membrane assay (Pasi et al. 1991).
However, morphine is cytotoxic to endothelial cells at such
high concentrations (Gupta et al. 2002), so the observed
effect could have been non-specific. In wound healing
experiments in mice, systemic administration of high-dose
morphine resulted in impared mobilization of endothelial
progenitor cells and angiogenesis, delaying the healing
process. Consistent with the in vivo experiment, in cultured
endothelial cells, morphine reduced capillary tube formation
in a concentration-dependent manner (Lam et al. 2008).
Effect of morphine on migration and invasiveness
of tumor cells
A major feature of cancer cells is their ability to migrate
and settle in surrounding or distant tissues. Most cancer
226 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230deaths and the main cause offailure in cancer treatment is not
due to growth of the primary tumor but results from its
intensive spread (metastasis) to secondary sites (Engbring and
Kleinman 2003; Widel and Widel 2006) .T h ec r i t i c a ls t e po f
cancer dissemination is migration of cancer cells through the
extracellular matrix (ECM). Indispensable in this process is
activation of urokinase plasminogen activator system, which
includes a serine proteinase, urokinase plasminogen activator
(uPA), two inhibitors, PAI-1 and PAI-2, and the membrane-
linked receptor (uPAR) (Duffy and Duggan 2004), plasmin
and matrix metalloproteinases (MMPs) (Mignatti and Rifkin
2000) capable of degrading the ECM.
It was shown that uPA, PAI-1, and uPAR levels are up-
regulated in most types of cancers (Shapiro et al. 1996).
The effect of morphine on uPA levels was studied in vitro
by several authors. Gach et al. (2009)s h o w e dt h a t
morphine caused a markedly increased secretion of uPA in
MCF-7 breast cancer cells, which correlated well with up-
regulation of uPA and uPAR mRNA levels. Naloxone
reversed morphine-induced up-regulation of uPA and uPA
mRNA levels confirming the involvement of the opioid
receptors in this process. A similar result was reported by
Nylund et al. (2008) who demonstrated that morphine
stimulated uPA secretion in HT-29 colon cancer cells.
The MMPs constitute a family of zinc-dependent endo-
peptidases, whose primary function is remodeling of compo-
nents in the ECM (Engbring and Kleinman 2003; Widel and
Widel 2006; Jespersen et al. 2009). Among the different
MMPs involved in degradation of ECM in cancer cells, it
seems that MMP-2 (gelatinase A) and MMP-9 (gelatinase B)
play a crucial role in cancer invasion because of their ability
to degrade type IV collagen, a major component of basement
membranes (Widel and Widel 2006). The activity of MMPs
is strictly regulated at the transcription and translation levels
by endogenous inhibitors, including α2-macroglobulin and
tissue inhibitors of metalloproteinases (TIMPs). Several
studies have shown that MMP expression and activity were
increased in several tumor types, especially breast and lung
cancer. The up-regulated levels of MMPs correlated well
with tumor stage, increased invasion, and potential metasta-
sis (Lynch and Matrisian 2002; Widel and Widel 2006).
Morphine was found to significantly reduce experimental
lung metastasis and invasion of colon 26-L5 cells by
inhibiting adhesion and migration of these cells to ECM
(Harimaya et al. 2002). In the mouse fibrosarcoma cell line,
WEHI164,activityofMMP-2was showntobeunder control
ofNOsystemandwasattenuatedbylowdosesofmorphinein
a non-opioid receptor-related manner (Shariftabrizi et al.
2006). In the MCF-7 cell line, morphine inhibited expression
and secretion of MMP-2 and -9 in time- and concentration-
dependent manner, and the process was not mediated by
opioid receptors but was also under the control of the NO
system (Gach et al. 2011).
Effect of morphine on immune system
Disorders in the immune system can result in disease,
including inflammatory diseases and cancer. Morphine
mediates its analgesic effect by the μ-opioid receptor. The
expression of the μ-opioid receptor gene in neuronal cells is
regulated by cytokines, released from the cells of the
immune system. On the other hand, μ-opioid receptor is
also expressed in the cells of immune system, such as
lymphocytes and macrophages (Börner et al. 2007). This
points at the importance of interactions between opioid and
immune system (Kraus 2009). The fact that morphine can
inhibit numerous immune cell functions and cause immu-
nosuppression is well known (Peterson et al. 1993;
Sacerdote et al. 1997; Eisenstein and Hilburger 1998). In
particular, morphine decreases the activity of natural killer
cells which play a major role in the rejection of tumors
(Sacerdote et al. 1997) and increases the susceptibility of
animals and humans to bacterial and viral infections
(Yeager et al. 1995; Risdahl et al. 1998; MacFarlane et al.
2000). It was also shown that morphine inhibits production
of pro-inflammatory cytokines (e.g., TNF, IL-6) in mono-
cytes (Bonnet et al. 2008), modulates the T helper cell
balance by inducing up-regulation of an anti-inflammatory
IL-4 mRNA (Roy et al. 2005) and produces immunosup-
pression by inhibition of transcription of IL-2 in activated
lymphocytes T (Börner et al. 2009). However, future
research is necessary to provide clearer understanding of
the cellular and molecular targets of morphine action within
the immune system.
Conclusions
For more than two decades, researchers have been trying to
document the effects that morphine exerts on tumor cells. It
has been recognized that morphine can affect tumor growth
by either directly acting on the tumor cells or by directly
acting on the endothelial cells or on the CNS-mediated
secretion of growth factors that may alter tumor microen-
vironment. Suppression of immune system by morphine
can be an additional complication. However, the results
obtained both in in vitro and in vivo studies are conflicting.
On one hand, morphine was shown to induce tumor growth,
inhibit apoptosis, promote angiogenesis and migration of
tumor cells, but on the other hand, pro-apoptotic and anti-
angiogenic properties of morphine were also demonstrated.
Performed studies were very heterogenic due to the
different doses of morphine applied, and the effects may
vary when the experiments were performed in vivo or on
isolated cells. The dose and route of administration of
morphine might be critical factors that need to be taken into
consideration in clinical settings. Contradictory results that
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230 227have been obtained induce further studies. The final answer
to the question whether morphine is an inhibitor of tumor
growth or whether it promotes cancer is still to be sought.
The effects of morphine can also depend on a cancer type,
since different cancer cells can overexpress certain enzymes
which are possible morphine targets.
Acknowledgements This work was supported by the grants from
the Medical University of Lodz (No 503/1-156-02/503-01, from
Polish Ministry of Science “Iuventus Plus” (No IP2010009470 for K.
G.) and ‘START’scholarship of the Foundation for Polish Science (for
K.G.).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
ArerangaiahR,ChalasaniN,UdagerAM,WeberML,ManivelJC,Griffin
RJ,SongCW ,Gupta K(2007)Opioidsinducerenalabnormalities in
tumor-bearing mice. Nephron Exp Nephrol 105:e80–e89
Ashkenazi A, Dixit VM (1999) Apoptosis control by death and decoy
receptors. Curr Opin Cell Biol 11:255–260
Balasubramanian S, Ramakrishnan S, Charboneau R, Wang J, Barke
RA, Roy S (2001) Morphine sulfate inhibits hypoxia-induced
vascular endothelial growth factor expression in endothelial cells
and cardiac myocytes. J Mol Cell Cardiol 33:2179–2187
Birnbaum Y ,Y eY , Rosanio S, Tavackoli S, Hu ZY , Schwarz ER, Uretsky
BF (2005) Prostaglandins mediate the cardioprotective effects of
atorvastatin against ischemia-reperfusion injury. Cardiovasc Res
65:345–355
Bonnet MP , Beloeil H, Benhamou D, Mazoit JX, Asehnoune K (2008)
The mu opioid receptor mediates morphine-induced tumor
necrosis factor and interleukin-6 inhibition in toll-like receptor
2-stimulated monocytes. Anesth Analg 106:1142–1149
Börner C, Stumm R, Hollt V , Kraus J (2007) Comparative analysis of
mu-opioid receptor expression in immune and neuronal cells. J
Neuroimmunol 188:56–63
Börner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B,
Höllt V , Kraus J (2009) Mechanisms of opioid-mediated
inhibition of human T cell receptor signaling. J Immunol
183:882–889
Brekken RA, Thorpe PE (2001) V ascular endothelial growth factor and
vascular targeting of solid tumors. Anticancer Res 21:4221–4229
Carmeliet P , Jain RK (2000) Angiogenesis in cancer and other
diseases. Nature 407:249–257
Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC,
Lane TF, Hla T (2004) Role of prostaglandin E2-dependent
angiogenic switch in cyclooxygenase 2-induced breast cancer
progression. Proc Natl Acad Sci USA 101:591–596
Chen C, Farooqui M, Gupta K (2006) Morphine stimulates vascular
endothelial growth factor-like signaling in mouse retinal endothelial
cells. Curr Neurovasc Res 3:171–180
Chen YL, Law PY , Loh HH (2008) The other side of the opioid story:
modulation of cell growth and survival signaling. Curr Med
Chem 15:772–778
Cheng WF, Chen LK, Chen CA, Chang MC, Hsiao PN, Su YN, Lee CN,
JengHJ, Hsieh CY , SunWZ (2006) ChimericDNAvaccine reverses
morphine-induced immunosuppression and tumorigenesis. Mol
Ther 13:203–210
Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular
life-or-death switch. Nat Rev Cancer 2:647–656
Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell
survival and oncogenesis. Oncogene 22:8590–8607
Crawford KW, Bowen WD (2002) Sigma-2 receptor agonists activate
a novel apoptotic pathway and potentiate antineoplastic drugs in
breast tumor cell lines. Cancer Res 62:313–322
Crawford KW, Coop A, Bowen WD (2002) Sigma(2) receptors
regulate changes in sphingolipid levels in breast tumor cells.
Eur J Pharmacol 443:207–209
Diao CT, Li L, Lau SY , Wong TM, Wong NS (2000) Kappa-opioid
receptor potentiates apoptosis via a phospholipase C pathway in
the CNE2 human epithelial tumor cell line. Biochim Biophys
Acta 1499:49–62
Duffy MJ, Duggan C (2004) The urokinase plasminogen activator
system: a rich source of tumour markers for the individualised
management of patients with cancer. Clin Biochem 37:541–548
Eisenstein TK, Hilburger ME (1998) Opioid modulation of immune
responses: effects on phagocyte and lymphoid cell populations. J
Neuroimmunol 83:36–44
Engbring JA, Kleinman HK (2003) The basement membrane matrix in
malignancy. J Pathol 200:465–470
Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Y ee D, Gupta K
(2006) Naloxone acts as an antagonist of estrogen receptor
activity in MCF-7 cells. Mol Cancer Ther 5:611–620
Farooqui M, Li Y , Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta
K (2007) COX-2 inhibitor celecoxib prevents chronic morphine-
induced promotion of angiogenesis, tumour growth, metastasis
and mortality, without compromising analgesia. Br J Cancer
97:1523–1531
Ferrara N (2004) V ascular endothelial growth factor: basic science and
clinical progress. Endocr Rev 25:581–611
Fichna J, Janecka A (2004) Opioid peptides in cancer. Cancer
Metastasis Rev 23:351–366
Folkman J, D’Amore PA (1996) Blood vessel formation: what is its
molecular basis? Cell 87:1153–1155
Fulda S, Debatin KM (2006) Modulation of apoptosis signaling for
cancer therapy. Arch Immunol Ther Exp (Warsz) 54:173–175
Gach K, Szemraj J, Fichna J, Piestrzeniewicz M, Delbro DS, Janecka
A (2009) The influence of opioids on urokinase plasminogen
activator on protein and mRNA level in MCF-7 breast cancer cell
line. Chem Biol Drug Des 74:390–396
Gach K, Szemraj J, Wyrebska A, Janecka A (2011) The influence of
opioids on matrix metalloproteinase-2 and -9 secretion and
mRNA levels in MCF-7 breast cancer cell line. Mol Biol Rep
38:1231–1236
Green DR, Reed JC (1998) Mitochondria and apoptosis. Science
281:1309–1312
Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW
(2002) Simultaneous inhibition of the receptor kinase activity of
vascular endothelial, fibroblast, and platelet-derived growth
factors suppresses tumor growth and enhances tumor radiation
response. Cancer Res 62:1702–1706
Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY , Yee D, Hebbel
RP (2002) Morphine stimulates angiogenesis by activating
proangiogenic and survival-promoting signaling and promotes
breast tumor growth. Cancer Res 62:4491–4498
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell
100:57–70
Harimaya Y , Koizumi K, Andoh T, Nojima H, Kuraishi Y , Saiki I
(2002) Potential ability of morphine to inhibit the adhesion,
invasion and metastasis of metastatic colon 26-L5 carcinoma
cells. Cancer Lett 187:121–127
Harrison LM, Kastin AJ, Zadina JE (1998) Opiate tolerance and
dependence: receptors, G-proteins, and antiopiates. Peptides
19:1603–1630
228 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230Hatsukari I, Hitosugi N, Matsumoto I, Nagasaka H, Sakagami H
(2003) Induction of early apoptosis marker by morphine in
human lung and breast carcinoma cell lines. Anticancer Res
23:2413–2417
Hatsukari I, Hitosugi N, Ohno R, Hashimoto K, Nakamura S, Satoh
K, Nagasaka H, Matsumoto I, Sakagami H (2007) Induction of
apoptosis by morphine in human tumor cell lines in vitro.
Anticancer Res 27:857–864
Hatzoglou A, Bakogeorgou E, Castanas E (1996) The antiproliferative
effect of opioid receptor agonists on the T47D human breast
cancer cell line, is partially mediated through opioid receptors.
Eur J Pharmacol 296:199–207
Hengartner MO (2000) The biochemistry of apoptosis. Nature
407:770–776
Hsiao PN, Chang MC, Cheng WF, Chen CA, Lin HW, Hsieh CY , Sun
WZ (2009) Morphine induces apoptosis of human endothelial
cells through nitric oxide and reactive oxygen species pathways.
Toxicology 256:83–91
Iglesias M, Segura MF, Comella JX, Olmos G (2003) Mu-opioid
receptor activation prevents apoptosis following serum with-
drawal in differentiated SH-SY5Y cells and cortical neurons via
phosphatidylinositol 3-kinase. Neuropharmacology 44(4):482–
492
Ishikawa M, Tanno K, Kamo A, Takayanagi Y , Sasaki K (1993)
Enhancement of tumor growth by morphine and its possible
mechanism in mice. Biol Pharm Bull 16:762–766
Janecka A, Fichna J, Kosson P , Zalewska-Kaszubska J, Krajewska U,
Mirowski M, Rozalski M (2004) Binding of the new morphi-
ceptin analogs to human MCF-7 breast cancer cells and their
effect on growth. Regul Pept 120:237–241
Jespersen C, Doller A, Akool e, Bachmann M, Muller R, Gutwein P ,
Muhl H, Pfeilschifter J, Eberhardt W (2009) Molecular mecha-
nisms of nitric oxide-dependent inhibition of TPA-induced matrix
metalloproteinase-9 (MMP-9) in MCF-7 cells. J Cell Physiol
219:276–287
Kapasi AA, Coscia SA, Pandya MP , Singhal PC (2004) Morphine
modulates HIV-1 gp160-induced murine macrophage and human
monocyte apoptosis bydisparateways. J Neuroimmunol148:86–96
Kaufmann SH, Hengartner MO (2001) Programmed cell death: alive
and well in the new millennium. Trends Cell Biol 11:526–534
Kawase M, Sakagami H, Furuya K, Kikuchi H, Nishikawa H,
Motohashi N, Morimoto Y , V arga A, Molnar J (2002) Cell
death-inducing activity of opiates in human oral tumor cell lines.
Anticancer Res 22:211–214
Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends
Pharmacol Sci 20:19–26
Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by
gene knockout. Prog Neurobiol 66:285–306
King T, V ardanyan A, Majuta L, Melemedjian O, Nagle R, Cress AE,
V anderah TW, Lai J, Porreca F (2007) Morphine treatment
accelerates sarcoma-induced bone pain, bone loss, and sponta-
neous fracture in a murine model of bone cancer. Pain 132:154–
168
Koodie L, Ramakrishnan S, Roy S (2010) Morphine suppresses tumor
angiogenesis through a HIF-1alpha/p38MAPK pathway. Am J
Pathol 177:984–997
Kraus J (2009) Regulation of mu-opioid receptors by cytokines. Front
Biosci 1:164–170, Schol. Ed
Lam CF, Chang PJ, Huang YS, Sung YH, Huang CC, Lin MW, Liu
YC, Tsai YC (2008) Prolonged use of high-dose morphine
impairs angiogenesis and mobilization of endothelial progenitor
cells in mice. Anesth Analg 107:686–692
Lazarczyk M, Matyja E, Lipkowski AW (2010) A comparative study
of morphine stimulation and biphalin inhibition of human
glioblastoma T98G cell proliferation in vitro. Peptides 31:1606–
1612
Leahy KM, Ornberg RL, Wang Y , Zweifel BS, Koki A T, Masferrer JL
(2002) Cyclooxygenase-2 inhibition by celecoxib reduces prolifer-
ation and induces apoptosis in angiogenic endothelial cells in vivo.
Cancer Res 62:625–631
L i nX ,L iQ ,W a n gY J ,J uY W ,C h iZ Q ,W a n gM W ,L i uJ G
(2007) Morphine inhibits doxorubicin-induced reactive oxy-
gen species generation and nuclear factor kappaB transcrip-
tional activation in neuroblastoma SH-SY5Y cells. Biochem J
406:215–221
Lin X, Wang YJ, Li Q, Hou YY , Hong MH, Cao YL, Chi ZQ, Liu JG
(2009) Chronic high-dose morphine treatment promotes SH-
SY5Y cell apoptosis via c-Jun N-terminal kinase-mediated
activation of mitochondria-dependent pathway. FEBS J
276:2022–2036
Lynch CC, Matrisian LM (2002) Matrix metalloproteinases in tumor-
host cell communication. Differentiation 70:561–573
MacFarlane AS, Peng X, Meissler JJ Jr, Rogers TJ, Geller EB, Adler
MW, Eisenstein TK (2000) Morphine increases susceptibility to
oral Salmonella typhimurium infection. J Infect Dis 181:1350–
1358
Maneckjee R, Biswas R, V onderhaar BK (1990) Binding of opioids to
human MCF-7 breast cancer cells and their effects on growth.
Cancer Res 50:2234–2238
Mantyh PW (2006) Cancer pain and its impact on diagnosis, survival
and quality of life. Nat Rev Neurosci 7:797–809
Mao J, Sung B, Ji RR, Lim G (2002) Neuronal apoptosis associated
with morphine tolerance: evidence for an opioid-induced neuro-
toxic mechanism. J Neurosci 22:7650–7661
Mathew B, Lennon F, Siegler J, Gerhold L, Mambetsariev N, Moreno-
Vinasco L, Garcia J, Salgia R, Moss J, Singleton P (2009) The
mu-opioid receptor regulates Lewis lung carcinoma tumor
growth and metastasis. Mol Cancer Ther 8:C78
Mignatti P , Rifkin DB (2000) Nonenzymatic interactions between
proteinases and the cell surface: novel roles in normal and
malignant cell physiology. Adv Cancer Res 78:103–157
Moon TD (1988) The effect of opiates upon prostatic carcinoma cell
growth. Biochem Biophys Res Commun 153:722–727
Moss J, Rosow CE (2008) Development of peripheral opioid
antagonists' new insights into opioid effects. Mayo Clin Proc
83:1116–1130
Nedelec E, Abid A, Cipolletta C, Presle N, Terlain B, Netter P , Jouzeau
J (2001) Stimulation of cyclooxygenase-2-activity by nitric
oxide-derived species in rat chondrocyte: lack of contribution to
loss of cartilage anabolism. Biochem Pharmacol 61:965–978
Nylund G, Pettersson A, Bengtsson C, Khorram-Manesh A, Nordgren
S, Delbro DS (2008) Functional expression of mu-opioid
receptors in the human colon cancer cell line, HT-29, and their
localization in human colon. Dig Dis Sci 53:461–466
Odunayo A, Dodam JR, Kerl ME, DeClue AE (2010) Immunomodula-
tory effects of opioids. J V et Emerg Crit Care 20:376–385 (San.
Antonio.)
Page GG, Ben-Eliyahu S, Yirmiya R, Liebeskind JC (1993) Morphine
attenuates surgery-induced enhancement of metastatic colonization
in rats. Pain 54:21–28
Pasi A, Qu BX, Steiner R, Senn HJ, Bar W, Messiha FS (1991)
Angiogenesis: modulation with opioids. Gen Pharmacol
22:1077–1079
PasternakGW(1993)Pharmacologicalmechanismsofopioidanalgesics.
Clin Neuropharmacol 16:1–18
Peterson PK, Molitor TW, Chao CC (1993) Mechanisms of morphine-
induced immunomodulation. Biochem Pharmacol 46:343–348
Rasmussen M, Zhu W, Tonnesen J, Cadet P , Tonnesen E, Stefano GB
(2002) Effects of morphine on tumour growth. Neuro Endocrinol
Lett 23:193–198
Reisine T, Bell GI (1993) Molecular biology of opioid receptors.
Trends Neurosci 16:506–510
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230 229Risdahl JM, Khanna KV , Peterson PK, Molitor TW (1998) Opiates
and infection. J Neuroimmunol 83:4–18
Roy S, Wang J, Charboneau R, Loh HH, Barke RA (2005) Morphine
induces CD4+ Tcell IL-4 expression through an adenylyl cyclase
mechanism independent of the protein kinase A pathway. J
Immunol 175:6361–6367
Sacerdote P , Manfredi B, Mantegazza P , Panerai AE (1997) Anti-
nociceptive and immunosuppressive effects of opiate drugs: a
structure-related activity study. Br J Pharmacol 121:834–840
Salvemini D, Misko TP , Masferrer JL, Seibert K, Currie MG,
Needleman P (1993) Nitric oxide activates cyclooxygenase
enzymes. Proc Natl Acad Sci USA 90:7240–7244
Salvemini D, Seibert K, Masferrer JL, Misko TP , Currie MG, Needleman
P (1994) Endogenous nitric oxide enhances prostaglandin produc-
tion in a model of renal inflammation. J Clin Invest 93:1940–1947
Sartorius U, Schmitz I, Krammer PH (2001) Molecular mechanisms of
death-receptor-mediated apoptosis. Chembiochem 2:20–29
Sasamura T, Nakamura S, Iida Y , Fujii H, Murata J, Saiki I, Nojima H,
Kuraishi Y (2002) Morphine analgesia suppresses tumor growth
and metastasis in a mouse model of cancer pain produced by
orthotopic tumor inoculation. Eur J Pharmacol 441:185–191
Schmitz R (1985) Friedrich Wilhelm Serturner and the discovery of
morphine. Pharm Hist 27:61–74
Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H,
Wilson EL, Rifkin DB (1996) Induction of primary cutaneous
melanocytic neoplasms in urokinase-type plasminogen activator
(uPA)-deficient and wild-type mice: cellular blue nevi invade but
do not progress to malignant melanoma in uPA-deficient animals.
Cancer Res 56:3597–3604
Shariftabrizi A, Nifli AP , Ansari M, Saadat F, Ebrahimkhani MR,
Alizadeh N, Nasseh A, Alexaki VI, Dehpour AR, Castanas E,
Khorramizadeh MR (2006) Matrix metalloproteinase 2 secretion
in WEHI 164 fibrosarcoma cells is nitric oxide-related and
modified by morphine. Eur J Pharmacol 530:33–39
Simon RH, Arbo TE (1986) Morphine increases metastatic tumor
growth. Brain Res Bull 16:363–367
Singleton PA, Moss J (2010) Effect of perioperative opioids on cancer
recurrence: a hypothesis. Future Oncol 6:1237–1242
Smith MT, Wright AW, Williams BE, Stuart G, Cramond T (1999)
Cerebrospinal fluid and plasma concentrations of morphine,
morphine-3-glucuronide, and morphine-6-glucuronide in patients
before and after initiation of intracerebroventricular morphine for
cancer pain management. Anesth Analg 88:109–116
Stefano GB, Hartman A, Bilfinger TV , Magazine HI, Liu Y , Casares F,
Goligorsky MS (1995) Presence of the mu3 opiate receptor in
endothelial cells. Coupling to nitric oxide production and
vasodilation. J Biol Chem 270:30290–30293
Sueoka N, Sueoka E, Okabe S, Fujiki H (1996) Anti-cancer effects of
morphine through inhibition of tumour necrosis factor-alpha
release and mRNA expression. Carcinogenesis 17:2337–2341
Sueoka E, Sueoka N, Kai Y , Okabe S, Suganuma M, Kanematsu K,
Yamamoto T, Fujiki H (1998) Anticancer activity of morphine
and its synthetic derivative, KT-90, mediated through apoptosis
and inhibition of NF-kappaB activation. Biochem Biophys Res
Commun 252:566–570
Suzuki S, Chuang LF, Doi RH, Chuang RY (2003) Morphine
suppresses lymphocyte apoptosis by blocking p53-mediated
death signaling. Biochem Biophys Res Commun 308:802–808
Tegeder I, Geisslinger G (2004) Opioids as modulators of cell death and
survival—unraveling mechanisms and revealing new indications.
Pharmacol Rev 56:351–369
Tegeder I, Grosch S, Schmidtko A, Haussler A, Schmidt H, Niederberger
E, Scholich K, Geisslinger G (2003) G protein-independent G1 cell
cycle block and apoptosis with morphine in adenocarcinoma cells:
involvement of p53 phosphorylation. Cancer Res 63:1846–1852
Ustun F, Durmus-Altun G, Altaner S, Tuncbilek N, Uzal C, Berkarda
S (2010) Evaluation of morphine effect on tumour angiogenesis
in mouse breast tumour model, EA TC. Med. Oncol (in press)
Wang CZ, Li XL, Sun S, Xie JT, Aung HH, Tong R, McEntee E, Y uan
CS (2009) Methylnaltrexone, a peripherally acting opioid
receptor antagonist, enhances tumoricidal effects of 5-Fu on
human carcinoma cells. Anticancer Res 29:2927–2932
Widel MS, Widel M (2006) Mechanisms of metastasis and molecular
markers of malignant tumor progression. I. Colorectal cancer.
Postepy Hig Med Dosw (Online) 60:453–470
Wu WR, Zheng JW, Li N, Bai HQ, Zhang KR, Li Y (1999)
Immunosuppressive effects of dihydroetorphine, a potent narcotic
analgesic, in dihydroetorphine-dependent mice. Eur J Pharmacol
366:261–269
Yeager MP , Colacchio TA (1991) Effect of morphine on growth of
metastatic colon cancer in vivo. Arch Surg 126:454–456
Yeager MP , Colacchio TA, Y u CT, Hildebrandt L, Howell AL, Weiss J,
Guyre PM (1995) Morphine inhibits spontaneous and cytokine-
enhanced natural killer cell cytotoxicity involunteers. Anesthesiology
83:500–508
Zadina JE, Kastin AJ, Ge LJ, Hackler L (1994) Mu, delta, and kappa
opiate receptor binding ofTyr-MIF-1 and ofTyr-W-MIF-1, its active
fragments, and two potent analogs. Life Sci 55:L461–L466
Zagon IS, Hytrek SD, Lang CM, Smith JP , McGarrity TJ, Wu Y ,
McLaughlin PJ (1996) Opioid growth factor ([Met5]enkephalin)
prevents the incidence and retards the growth of human colon
cancer. Am J Physiol 271:R780–R786
Zong J, Pollack GM (2000) Morphine antinociception is enhanced in
mdr1a gene-deficient mice. Pharm Res 17:749–753
230 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:221–230